Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
National Immunobiologicheskaja Company (Natsimbio), one of Russia’s largest vaccines producers that is part of the local state corporation Rostec, has announced plans to launch the production of a vaccine for the prevention of pneumococcal disease during the next several years, The Pharma Letter’s local correspondent reports. 6 October 2016
All the drugs presenting on the Russian market will have to be labeled by a QR-code with the aim of preventing counterfeiting, according to recent statements of Denis Manturov, Russia’s Minister of Industry and Trade, reports The Pharma Letter’s local correspondent. 6 October 2016
The board of directors of the Swiss Galenica Group has designated Stefan Schulze, currently chief executive of group company Vifor Fresenius Medical Care Renal Pharma (VFMCRP), as chief operating officer and president of the executive committee of Vifor Pharma. 6 October 2016
Astellas Pharma has appointed Steven Benner as senior vice president and therapeutic area head for oncology, and promoted Anne Keating to vice president of clinical science for oncology, within the company's development organization. 6 October 2016
In our weekly expert view, head of oncology at German pharma company Bayer looks at the evolution of cancer treatments over the past two decades and looks ahead to what the future might look like. 5 October 2016
Santhera Pharmaceuticals has appointed Kristina Timdahl as chief medical officer and head of development and a member of the executive management with effect from January 1, 2017. 5 October 2016
Robert Mulroy, the chief executive of USA-based Merrimack Pharmaceuticals has resigned after 17 years in the role as the company undergoes a major restructuring which will see its workforce cut by 22%. 4 October 2016
Cham Herath, medical director at Italian drugmaker Chiesi Farmaceutici, knew that news of his company’s progress this month with a first-of-its-kind triple combination in chronic obstructive pulmonary disease (COPD) might not gain as much attention as it probably should, for two reasons. 3 October 2016
The number of people dying from opioid or heroin overdoses has nearly quadrupled in the US since the beginning of century leading to increased scrutiny of laws around prescription opioids and calls on the pharma industry to take more responsibility. Joel Levy takes an in-depth look at the issue. 3 October 2016
The Russian Federal Antimonopoly Service (FAS) may cancel registration of certain imported drugs, which are presented in the Russian market, due to the pricing policy, which is implemented by their producers, according to an official spokesman for the agency, reports The Pharma Letter’s local correspondent. 30 September 2016
UK pharma major GlaxoSmithKline today announced that Brian McNamara has been appointed chief executive of GSK’s Consumer Healthcare division effective immediately. 29 September 2016
When Mary Mitchell-O’Connor, Ireland’s Minister of Jobs, Enterprise and Innovation, was speaking at a Dublin conference last week, she could have used countless statistics to demonstrate the strength of her country’s pharmaceutical sector. 26 September 2016
Thierry Diagnana, head of the Novartis Institutue for Tropical Diseases (NITD), speaks to the Pharma Letter’s Katie Osborne about a new anti-malarial molecule, KAF156, which could be a game-changer in the treatment landscape. 23 September 2016